Cargando…

A human liver chimeric mouse model for non-alcoholic fatty liver disease

BACKGROUND & AIMS: The accumulation of neutral lipids within hepatocytes underlies non-alcoholic fatty liver disease (NAFLD), which affects a quarter of the world’s population and is associated with hepatitis, cirrhosis, and hepatocellular carcinoma. Despite insights gained from both human and a...

Descripción completa

Detalles Bibliográficos
Autores principales: Bissig-Choisat, Beatrice, Alves-Bezerra, Michele, Zorman, Barry, Ochsner, Scott A., Barzi, Mercedes, Legras, Xavier, Yang, Diane, Borowiak, Malgorzata, Dean, Adam M., York, Robert B., Galvan, N. Thao N., Goss, John, Lagor, William R., Moore, David D., Cohen, David E., McKenna, Neil J., Sumazin, Pavel, Bissig, Karl-Dimiter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8138774/
https://www.ncbi.nlm.nih.gov/pubmed/34036256
http://dx.doi.org/10.1016/j.jhepr.2021.100281
_version_ 1783695874651586560
author Bissig-Choisat, Beatrice
Alves-Bezerra, Michele
Zorman, Barry
Ochsner, Scott A.
Barzi, Mercedes
Legras, Xavier
Yang, Diane
Borowiak, Malgorzata
Dean, Adam M.
York, Robert B.
Galvan, N. Thao N.
Goss, John
Lagor, William R.
Moore, David D.
Cohen, David E.
McKenna, Neil J.
Sumazin, Pavel
Bissig, Karl-Dimiter
author_facet Bissig-Choisat, Beatrice
Alves-Bezerra, Michele
Zorman, Barry
Ochsner, Scott A.
Barzi, Mercedes
Legras, Xavier
Yang, Diane
Borowiak, Malgorzata
Dean, Adam M.
York, Robert B.
Galvan, N. Thao N.
Goss, John
Lagor, William R.
Moore, David D.
Cohen, David E.
McKenna, Neil J.
Sumazin, Pavel
Bissig, Karl-Dimiter
author_sort Bissig-Choisat, Beatrice
collection PubMed
description BACKGROUND & AIMS: The accumulation of neutral lipids within hepatocytes underlies non-alcoholic fatty liver disease (NAFLD), which affects a quarter of the world’s population and is associated with hepatitis, cirrhosis, and hepatocellular carcinoma. Despite insights gained from both human and animal studies, our understanding of NAFLD pathogenesis remains limited. To better study the molecular changes driving the condition we aimed to generate a humanised NAFLD mouse model. METHODS: We generated TIRF (transgene-free Il2rg(-/-)/Rag2(-/-)/Fah(-/-)) mice, populated their livers with human hepatocytes, and fed them a Western-type diet for 12 weeks. RESULTS: Within the same chimeric liver, human hepatocytes developed pronounced steatosis whereas murine hepatocytes remained normal. Unbiased metabolomics and lipidomics revealed signatures of clinical NAFLD. Transcriptomic analyses showed that molecular responses diverged sharply between murine and human hepatocytes, demonstrating stark species differences in liver function. Regulatory network analysis indicated close agreement between our model and clinical NAFLD with respect to transcriptional control of cholesterol biosynthesis. CONCLUSIONS: These NAFLD xenograft mice reveal an unexpected degree of evolutionary divergence in food metabolism and offer a physiologically relevant, experimentally tractable model for studying the pathogenic changes invoked by steatosis. LAY SUMMARY: Fatty liver disease is an emerging health problem, and as there are no good experimental animal models, our understanding of the condition is poor. We here describe a novel humanised mouse system and compare it with clinical data. The results reveal that the human cells in the mouse liver develop fatty liver disease upon a Western-style fatty diet, whereas the mouse cells appear normal. The molecular signature (expression profiles) of the human cells are distinct from the mouse cells and metabolic analysis of the humanised livers mimic the ones observed in humans with fatty liver. This novel humanised mouse system can be used to study human fatty liver disease.
format Online
Article
Text
id pubmed-8138774
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-81387742021-05-24 A human liver chimeric mouse model for non-alcoholic fatty liver disease Bissig-Choisat, Beatrice Alves-Bezerra, Michele Zorman, Barry Ochsner, Scott A. Barzi, Mercedes Legras, Xavier Yang, Diane Borowiak, Malgorzata Dean, Adam M. York, Robert B. Galvan, N. Thao N. Goss, John Lagor, William R. Moore, David D. Cohen, David E. McKenna, Neil J. Sumazin, Pavel Bissig, Karl-Dimiter JHEP Rep Research Article BACKGROUND & AIMS: The accumulation of neutral lipids within hepatocytes underlies non-alcoholic fatty liver disease (NAFLD), which affects a quarter of the world’s population and is associated with hepatitis, cirrhosis, and hepatocellular carcinoma. Despite insights gained from both human and animal studies, our understanding of NAFLD pathogenesis remains limited. To better study the molecular changes driving the condition we aimed to generate a humanised NAFLD mouse model. METHODS: We generated TIRF (transgene-free Il2rg(-/-)/Rag2(-/-)/Fah(-/-)) mice, populated their livers with human hepatocytes, and fed them a Western-type diet for 12 weeks. RESULTS: Within the same chimeric liver, human hepatocytes developed pronounced steatosis whereas murine hepatocytes remained normal. Unbiased metabolomics and lipidomics revealed signatures of clinical NAFLD. Transcriptomic analyses showed that molecular responses diverged sharply between murine and human hepatocytes, demonstrating stark species differences in liver function. Regulatory network analysis indicated close agreement between our model and clinical NAFLD with respect to transcriptional control of cholesterol biosynthesis. CONCLUSIONS: These NAFLD xenograft mice reveal an unexpected degree of evolutionary divergence in food metabolism and offer a physiologically relevant, experimentally tractable model for studying the pathogenic changes invoked by steatosis. LAY SUMMARY: Fatty liver disease is an emerging health problem, and as there are no good experimental animal models, our understanding of the condition is poor. We here describe a novel humanised mouse system and compare it with clinical data. The results reveal that the human cells in the mouse liver develop fatty liver disease upon a Western-style fatty diet, whereas the mouse cells appear normal. The molecular signature (expression profiles) of the human cells are distinct from the mouse cells and metabolic analysis of the humanised livers mimic the ones observed in humans with fatty liver. This novel humanised mouse system can be used to study human fatty liver disease. Elsevier 2021-03-21 /pmc/articles/PMC8138774/ /pubmed/34036256 http://dx.doi.org/10.1016/j.jhepr.2021.100281 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Research Article
Bissig-Choisat, Beatrice
Alves-Bezerra, Michele
Zorman, Barry
Ochsner, Scott A.
Barzi, Mercedes
Legras, Xavier
Yang, Diane
Borowiak, Malgorzata
Dean, Adam M.
York, Robert B.
Galvan, N. Thao N.
Goss, John
Lagor, William R.
Moore, David D.
Cohen, David E.
McKenna, Neil J.
Sumazin, Pavel
Bissig, Karl-Dimiter
A human liver chimeric mouse model for non-alcoholic fatty liver disease
title A human liver chimeric mouse model for non-alcoholic fatty liver disease
title_full A human liver chimeric mouse model for non-alcoholic fatty liver disease
title_fullStr A human liver chimeric mouse model for non-alcoholic fatty liver disease
title_full_unstemmed A human liver chimeric mouse model for non-alcoholic fatty liver disease
title_short A human liver chimeric mouse model for non-alcoholic fatty liver disease
title_sort human liver chimeric mouse model for non-alcoholic fatty liver disease
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8138774/
https://www.ncbi.nlm.nih.gov/pubmed/34036256
http://dx.doi.org/10.1016/j.jhepr.2021.100281
work_keys_str_mv AT bissigchoisatbeatrice ahumanliverchimericmousemodelfornonalcoholicfattyliverdisease
AT alvesbezerramichele ahumanliverchimericmousemodelfornonalcoholicfattyliverdisease
AT zormanbarry ahumanliverchimericmousemodelfornonalcoholicfattyliverdisease
AT ochsnerscotta ahumanliverchimericmousemodelfornonalcoholicfattyliverdisease
AT barzimercedes ahumanliverchimericmousemodelfornonalcoholicfattyliverdisease
AT legrasxavier ahumanliverchimericmousemodelfornonalcoholicfattyliverdisease
AT yangdiane ahumanliverchimericmousemodelfornonalcoholicfattyliverdisease
AT borowiakmalgorzata ahumanliverchimericmousemodelfornonalcoholicfattyliverdisease
AT deanadamm ahumanliverchimericmousemodelfornonalcoholicfattyliverdisease
AT yorkrobertb ahumanliverchimericmousemodelfornonalcoholicfattyliverdisease
AT galvannthaon ahumanliverchimericmousemodelfornonalcoholicfattyliverdisease
AT gossjohn ahumanliverchimericmousemodelfornonalcoholicfattyliverdisease
AT lagorwilliamr ahumanliverchimericmousemodelfornonalcoholicfattyliverdisease
AT mooredavidd ahumanliverchimericmousemodelfornonalcoholicfattyliverdisease
AT cohendavide ahumanliverchimericmousemodelfornonalcoholicfattyliverdisease
AT mckennaneilj ahumanliverchimericmousemodelfornonalcoholicfattyliverdisease
AT sumazinpavel ahumanliverchimericmousemodelfornonalcoholicfattyliverdisease
AT bissigkarldimiter ahumanliverchimericmousemodelfornonalcoholicfattyliverdisease
AT bissigchoisatbeatrice humanliverchimericmousemodelfornonalcoholicfattyliverdisease
AT alvesbezerramichele humanliverchimericmousemodelfornonalcoholicfattyliverdisease
AT zormanbarry humanliverchimericmousemodelfornonalcoholicfattyliverdisease
AT ochsnerscotta humanliverchimericmousemodelfornonalcoholicfattyliverdisease
AT barzimercedes humanliverchimericmousemodelfornonalcoholicfattyliverdisease
AT legrasxavier humanliverchimericmousemodelfornonalcoholicfattyliverdisease
AT yangdiane humanliverchimericmousemodelfornonalcoholicfattyliverdisease
AT borowiakmalgorzata humanliverchimericmousemodelfornonalcoholicfattyliverdisease
AT deanadamm humanliverchimericmousemodelfornonalcoholicfattyliverdisease
AT yorkrobertb humanliverchimericmousemodelfornonalcoholicfattyliverdisease
AT galvannthaon humanliverchimericmousemodelfornonalcoholicfattyliverdisease
AT gossjohn humanliverchimericmousemodelfornonalcoholicfattyliverdisease
AT lagorwilliamr humanliverchimericmousemodelfornonalcoholicfattyliverdisease
AT mooredavidd humanliverchimericmousemodelfornonalcoholicfattyliverdisease
AT cohendavide humanliverchimericmousemodelfornonalcoholicfattyliverdisease
AT mckennaneilj humanliverchimericmousemodelfornonalcoholicfattyliverdisease
AT sumazinpavel humanliverchimericmousemodelfornonalcoholicfattyliverdisease
AT bissigkarldimiter humanliverchimericmousemodelfornonalcoholicfattyliverdisease